A detailed history of Financial Advocates Investment Management transactions in Inmune Bio, Inc. stock. As of the latest transaction made, Financial Advocates Investment Management holds 13,500 shares of INMB stock, worth $60,615. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,500
Previous 11,500 17.39%
Holding current value
$60,615
Previous $101,000 28.71%
% of portfolio
0.0%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$4.86 - $9.86 $9,720 - $19,720
2,000 Added 17.39%
13,500 $72,000
Q2 2024

Jul 26, 2024

BUY
$7.15 - $11.84 $7,150 - $11,840
1,000 Added 9.52%
11,500 $101,000
Q1 2024

May 01, 2024

SELL
$10.53 - $14.01 $21,060 - $28,020
-2,000 Reduced 16.0%
10,500 $123,000
Q4 2023

Feb 08, 2024

BUY
$6.6 - $11.52 $82,500 - $144,000
12,500 New
12,500 $140,000
Q1 2023

May 11, 2023

SELL
$6.01 - $10.18 $12,927 - $21,897
-2,151 Reduced 15.76%
11,500 $74,000
Q4 2022

Feb 14, 2023

BUY
$6.13 - $7.96 $83,680 - $108,661
13,651 New
13,651 $86,000
Q4 2021

Feb 14, 2022

SELL
$9.97 - $20.38 $14,955 - $30,570
-1,500 Reduced 9.0%
15,167 $155,000
Q3 2021

Nov 04, 2021

SELL
$14.13 - $27.85 $42,390 - $83,550
-3,000 Reduced 15.25%
16,667 $324,000
Q1 2021

May 10, 2021

BUY
$11.61 - $26.85 $17,415 - $40,275
1,500 Added 8.26%
19,667 $234,000
Q3 2020

Nov 04, 2020

SELL
$4.92 - $15.75 $1.07 Million - $3.43 Million
-217,794 Reduced 92.3%
18,167 $187,000
Q2 2020

Aug 14, 2020

SELL
$3.1 - $6.09 $54,250 - $106,575
-17,500 Reduced 6.9%
235,961 $1.24 Million
Q1 2020

Apr 29, 2020

BUY
$2.21 - $6.15 $63,634 - $177,083
28,794 Added 12.82%
253,461 $844,000
Q3 2019

Nov 13, 2019

BUY
$5.32 - $10.0 $1.2 Million - $2.25 Million
224,667 New
224,667 $1.33 Million

Others Institutions Holding INMB

About Inmune Bio, Inc.


  • Ticker INMB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,946,000
  • Market Cap $80.6M
  • Description
  • INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...
More about INMB
Track This Portfolio

Track Financial Advocates Investment Management Portfolio

Follow Financial Advocates Investment Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Financial Advocates Investment Management, based on Form 13F filings with the SEC.

News

Stay updated on Financial Advocates Investment Management with notifications on news.